Ignite Creation Date:
2024-05-06 @ 8:34 AM
Last Modification Date:
2024-10-26 @ 12:02 PM
Study NCT ID:
NCT02769767
Status:
UNKNOWN
Last Update Posted:
2016-05-12
First Post:
2016-04-25
Brief Title:
Polymorphisms of Interleukins Glypican and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis
Sponsor:
Instituto Jalisciense de Cancerologia
Organization:
Instituto Jalisciense de Cancerologia
Study Overview
Official Title:
Association of Polymorphisms of the Interleukin-7 Receptor-α IL-7R Glypican 5 GPC5 Interleukin-2 Receptor-α IL2-RA Human Leukocyte Antigen Class II Beta Chain HLA-DRB1 Genes and Treatment Response in Multiple Sclerosis MS
Status:
UNKNOWN
Status Verified Date:
2016-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
WESTEMDRB1
Brief Summary:
HLA-DRB1 Gene and some genes involved in inflammation and immunity IL-7R GPC5 CTSS have been linked to risk of MS and the response to treatment with immunomodulators This research aims to estimate the risk that confers some variations in the sequence of these genes
Detailed Description:
Genes HLA-DRB1 and some genes involved in inflammation and immunity have been linked to risk of MS and the response to treatment with immunomodulators
The HLA-DRB1 genes have been associated with risk and response to treatment in MS in multiple studies however other genes have been controversial This research aims to estimate the risk for MS that confers some variations in the sequence of IL-7R GPC5 CTSS HLA-DRB1 genes Furthermore it seeks to determine whether these gene variants polymorphisms are associated with treatment response to immunomodulators
Subjects with MS and healthy subjects will be taken to assess the risk for MS Besides the investigators obtain the medical history of relapse to assess response to treatment in accordance with Expanded Disability Status Scale EDSS and relapses
The HLA-DRB1 genes have been associated with risk and response to treatment in MS in multiple studies however other genes have been controversial This research aims to estimate the risk for MS that confers some variations in the sequence of IL-7R GPC5 CTSS HLA-DRB1 genes Furthermore it seeks to determine whether these gene variants polymorphisms are associated with treatment response to immunomodulators
Subjects with MS and healthy subjects will be taken to assess the risk for MS Besides the investigators obtain the medical history of relapse to assess response to treatment in accordance with Expanded Disability Status Scale EDSS and relapses
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None